H. Lee Moffitt Cancer Center & Research Institute

Physician, Faculty, and Staff

Robert M. Wenham, MD, MS, FACOG

Robert M. Wenham, MD, MS, FACOG

Faculty Rank:

Assistant Member

Titles:

  • Principal Investigator, Gynecologic Oncology Group
  • Medical Director, Clinical Research Network
  • Principal Investigator, TCC Protocol

Department/Program Affiliations:

  • Gynecologic Oncology  
  • Experimental Therapeutics  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Consultation/Referral Phone:

(813) 745-8450

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences

University Academic Rank:

Assistant Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Robert M. Wenham, MD, MS, FACOG

Education & Training:

  • MSc, University of North Texas Health Science Center, Fort Worth, TX, 1993 - Biochemistry and Molecular Biology
  • MD, University of Texas Southwestern Medical School, 1997 - Medicine
  • Internship/Residency, Harvard, Brigham and Women's Hospital and Massachusetts General Hospital, 2001 - Obstetrics and Gynecology
  • Fellowship, Duke University Medical Center, 2004 - Gynecologic Oncology

General Board Certification / SubSpecialty:

  • Obstetrics & Gynecology / Gynecologic Oncology

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Robert M. Wenham, MD, MS, FACOG

Research Interests:

Dr. Wenham's research involves identifying and testing novel biological agents and chemotherapeutics for gynecologic cancers.  He is a Principal Investigator of the Gyncelogic Oncology Group.  He is also Principal Investigator of the Moffitt Total Cancer Care protocol and medical director of the Moffitt Clinical Research Network.


Clinical Interests:

Dr. Wenham sees patients with a range of gynecologic oncology problems. He has particular interest in potentially curative salvage surgeries for localized pelvic recurrences.


For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Robert M. Wenham, MD, MS, FACOG

Publications:

  1. Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2010 Jul. Pubmedid: 20644979.   Pubmed ID: 20644979

  2. Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol. 2010 Aug;203(2):158.e1-158.40. Pubmedid: 20444440.   Pubmed ID: 20444440

  3. Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM. Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. J Surg Oncol. 2009 Nov;100(6):511-514. Pubmedid: 19697350.   Pubmed ID: 19697350

  4. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009 Jan;16(1):8-13. Pubmedid: 19078924.   Pubmed ID: 19078924

  5. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009 May;113(2):249-233. Pubmedid: 19237188.   Pubmed ID: 19237188

  6. Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila Pa). 2009 Feb;2(2):114-121. Pubmedid: 19174584.   Pubmed ID: 19174584

  7. Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS. Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows. Am J Obstet Gynecol. 2009 Jul;201(1):116.e1-116.e3. Pubmedid: 19576378.   Pubmed ID: 19576378

  8. Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int J Gynecol Cancer. 2009 Dec;19(9):1564-1569. Pubmedid: 19955938.   Pubmed ID: 19955938

  9. Marquez CB, Smithberger EE, Bair SM, Wenham RM, Fenske NA, Glass LF, Cherpelis BS. Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control. 2009 Jan;16(1):66-69. Pubmedid: 19078932.   Pubmed ID: 19078932

  10. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D, Dressman H, Lancaster J. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008 Aug;110(2):206-215. Pubmedid: 18499237.   Pubmed ID: 18499237

  11. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cellsurvival and cisplatin resistance by targeting PTEN. Cancer Res. 2008 Jan;68(2):425-433. Pubmedid: 18199536.   Pubmed ID: 18199536

  12. Donovan K, Taliaferro L, Alvarez E, Jacobsen P, Roetzheim R, Wenham R. Sexual health in women treated for cervical cancer: Characteristics and correlates. Gynecol Oncol. 2007 Feb;104(2):428-434. Pubmedid: 17005248.   Pubmed ID: 17005248

  13. Hoyo C, Grubber J, Demark-Wahnefried W, Marks JR, Freedland SJ, Jeffreys AS, Grambow SC, Wenham RM, Walther PJ, Schildkraut JM. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. J Natl Med Assoc. 2007 Jul;99(7):718-722. Pubmedid: 17668637.   Pubmed ID: 17668637

  14. Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-2147. Pubmedid: 15598772.   Pubmed ID: 15598772

  15. Wenham R, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, LancasterJM, Schildkraut J, Marks J, Berchuck A. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovariancancer. J Soc Gynecol Investig. 2003;10:381-387. Pubmedid: 12969782.   Pubmed ID: 12969782

  16. Wenham R, Schildkraut J, McLean K, Calingaert B, Bentley R, Marks J, Berchuck A. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003;9(12):4396-4403. Pubmedid: 14555511.   Pubmed ID: 14555511

  17. Garrett A, Wenham R, Onderdonk A, Sheets E. Can Monsel's Transmit Nosocomial Infections? A Microbiological Investigation. J Low Genit Tract Dis. 2002 Oct;6(4):228-231. Pubmedid: 17051028.   Pubmed ID: 17051028

  18. Garrett A, Wenham R, Sheets E. Monsel's Solution: A Brief History. J Low Genit Tract Dis. 2002 Oct;6(4):225-227. Pubmedid: 17051027.   Pubmed ID: 17051027

  19. Lea J, Sheets E, Wenham R, Duska L, Coleman R, Miller D, Schorge J. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol. 2002;84(1):115-119. Pubmedid: 11748986.   Pubmed ID: 11748986

  20. Wenham R, Lancaster J, Berchuck A. Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16(4):483-497. Pubmedid: 12413930.   Pubmed ID: 12413930

Robert M. Wenham, MD, MS, FACOG

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Phase II Study of Adding AMG 479,Fully Human Momoclonal Antibody Against Insulin Like Growth Factor in Ovarian CC
Sponsor: Amgen, Inc.
Project Dates: December 2, 2008 to December 1, 2010
Earned to Date: $12,500

Phase I study of AMG 386 in Combination with either Pegylated
Sponsor: Amgen, Inc.
Project Dates: June 16, 2008 to June 15, 2011
Annual Direct Cost: $8,080
Annual Total Cost: $10,504
Project Total: $54,085

Ixabepitone VS Paclitaxel or Doxorubicin in Women with ADV recurrent endometrial Cancer
Sponsor: Bristol Myers Squibb Company
Project Dates: October 14, 2009 to October 13, 2011
Earned to Date: $17,214

SRC Kinase Inhibitor , Dasatinib in Comb with Paclitaxel & Carboplatin in Ovarian CA
Sponsor: Duke Univ
Project Dates: April 2, 2007 to April 1, 2012
Annual Direct Cost: $7,465
Annual Total Cost: $9,705
Project Total: $54,336

GDC 0449 as maintenance therapy in pts with ovarian CA in 2nd or 3rd complete remission
Sponsor: Genentech, Inc.
Project Dates: February 10, 2009 to February 9, 2011
Earned to Date: $9,500

Phase II Study of Bevacizumab in Combination with Docetaxel in Pts with Epithelial Carcinoma of Ovary
Sponsor: Genentech, Inc.
Project Dates: November 14, 2006 to November 13, 2010
Annual Direct Cost: $102,928
Annual Total Cost: $128,660
Project Total: $295,588

GOG Clinical Trials

27469-096
Sponsor: Gynecologic Oncology Group / Nat Institutes of Health
Project Dates: April 1, 2004 to March 31, 2016
Earned to Date: $0

Phase 1A Study of MK-4827 in Patients with Advanced Solid Tumors
Sponsor: Merck & Co., Inc.
Project Dates: September 19, 2008 to September 18, 2011
Earned to Date: $316,966

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute